- Trial phase
- Approved
- Time to market
- Already approved and marketed in the EU (since June 2016) and multiple ex-US countries. Pediatric use from birth was authorized by the EMA following a CHMP positive opinion in September 2024.
- Why 3/10
- Zavicefta is already approved and marketed in the EU and ex-US regions with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next 12 months; the CHMP positive opinion for pediatric expansion was issued in September 2024 and is already incorporated. As a mature product within Pfizer's $62.6B revenue base, even a material change in Zavicefta's sales would have negligible impact on PFE shares.
Zavicefta is a mature, marketed product with no upcoming binary catalyst. Watch for generic/biosimilar erosion timelines in ex-US markets and any new resistance data that could shift usage patterns, but neither is likely to move Pfizer's stock given the drug's small revenue contribution.
Price Chart
Executive Summary
Zavicefta (ceftazidime/avibactam) is an IV antibiotic for multi-drug-resistant Gram-negative infections, approved in the EU since 2016 and marketed by Pfizer in ex-US territories. Pfizer acquired the rights from AstraZeneca in 2016 for $1.5B. In the US, the same drug is sold as Avycaz by AbbVie. Zavicefta is on the WHO Essential Medicines List as a RESERVE-group antibiotic for carbapenem-resistant infections. The drug is a mature, commercial-stage product with no upcoming binary regulatory catalyst. It is a very small contributor to Pfizer's $62.6B annual revenue, making it essentially immaterial to PFE's stock price.
How It Works
Zavicefta combines two active ingredients in one IV infusion: ceftazidime (a cephalosporin antibiotic that kills bacteria by weakening their cell walls) and avibactam (a beta-lactamase inhibitor that blocks enzymes bacteria use to destroy ceftazidime). The avibactam component protects ceftazidime from being broken down, allowing it to work against multi-drug-resistant Gram-negative bacteria that would otherwise be untreatable.
Trial Status
Zavicefta is a marketed drug. Post-approval activities include a Phase 2a pediatric PK study (completed, supporting label expansion from birth) and a post-marketing special investigation in Japan (observational, not yet recruiting as of October 2025). No pivotal Phase 3 trials are ongoing.
The Two-Sided Case
Upcoming Catalysts
- No hard binary catalysts (PDUFA, pivotal readout, AdComm) are scheduled for Zavicefta in the next 12 months.
- Watch for generic entry timelines as patents approach expiry in various ex-US markets.
- Ongoing real-world evidence studies and antimicrobial stewardship guideline updates could incrementally affect usage.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report